Cite
HARVARD Citation
Pellicelli, A. et al. (n.d.). Daclatasvir/sofosbuvir and ribavirin 800 mg flat dose is highly efficacy and safe in genotype 3 compensated and decompensated cirrhotic patients: The CLEO experience. Digestive and liver disease. 49 (1), pp. e64-. [Online].